Search research articles
Contact Us
Filters
Showing results (31-40 of 124) with videos related to
Page
of 13
Sort By:
Hematological Oncology
|
March 29, 2016
Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series
Joshua Richter, Noa Biran, Narjust Duma, et al.
American Journal of Hematology
|
January 25, 2024
Soluble B-cell maturation antigen in multiple myeloma
Bruno Almeida Costa, Ricardo J Ortiz, Alexander M Lesokhin, et al.
Clinics in Geriatric Medicine
|
February 14, 2012
Liquid tumors in the elderly
Anthony Mato, Tatyana Feldman, Joshua Richter, et al.
Critical Reviews in Oncology/Hematology
|
May 27, 2023
Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives
Bruno Almeida Costa, Tarek H Mouhieddine, Ricardo J Ortiz, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
February 22, 2021
Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab
Joshua Richter, Vamshi Ruthwik Anupindi, Jason Yeaw, et al.
Future Oncology (London, England)
|
March 12, 2021
Management of patients with difficult-to-treat multiple myeloma
Joshua Richter, Karthik Ramasamy, Leo Rasche, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 9, 2020
Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma
Tarek H Mouhieddine, Yasir Ahmad, Bart Barlogie, et al.
Expert Review of Hematology
|
December 17, 2020
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma
Shambavi Richard, Sundar Jagannath, Hearn Jay Cho, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 7, 2020
Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation
Liana Nikolaenko, Saurabh Chhabra, Noa Biran, et al.
Annals of Hematology
|
September 12, 2024
Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study
Csaba Siffel, Joshua Richter, Colin Anderson-Smits, et al.
Page
of 13
Search research articles
Search
Showing results (31-40 of 124) with videos related to
Sort By:
Page
of 13
Hematological Oncology
|
March 29, 2016
Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series
Joshua Richter, Noa Biran, Narjust Duma, et al.
American Journal of Hematology
|
January 25, 2024
Soluble B-cell maturation antigen in multiple myeloma
Bruno Almeida Costa, Ricardo J Ortiz, Alexander M Lesokhin, et al.
Clinics in Geriatric Medicine
|
February 14, 2012
Liquid tumors in the elderly
Anthony Mato, Tatyana Feldman, Joshua Richter, et al.
Critical Reviews in Oncology/Hematology
|
May 27, 2023
Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives
Bruno Almeida Costa, Tarek H Mouhieddine, Ricardo J Ortiz, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
February 22, 2021
Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab
Joshua Richter, Vamshi Ruthwik Anupindi, Jason Yeaw, et al.
Future Oncology (London, England)
|
March 12, 2021
Management of patients with difficult-to-treat multiple myeloma
Joshua Richter, Karthik Ramasamy, Leo Rasche, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 9, 2020
Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma
Tarek H Mouhieddine, Yasir Ahmad, Bart Barlogie, et al.
Expert Review of Hematology
|
December 17, 2020
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma
Shambavi Richard, Sundar Jagannath, Hearn Jay Cho, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 7, 2020
Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation
Liana Nikolaenko, Saurabh Chhabra, Noa Biran, et al.
Annals of Hematology
|
September 12, 2024
Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study
Csaba Siffel, Joshua Richter, Colin Anderson-Smits, et al.
Page
of 13